This analysis shows similarities with our work, since it included a large subgroup of HR-positive/HER2-positive BC patients (3603, of whom 1888 were premenopausal) from a clinical trial dedicated to HER2-positive BC patients all treated with adjuvant anti-HER2 therapy6. Here, ERBB2 is linked to breast cancer.